My apologies, it was Scott Kelly who spoke about b
Post# of 148150
It wasn’t Daniel Adams from CreatV BioTech.
Scott Kelly -
“As we move forward we will continue to look for biomarkers to show the effectiveness of Leronlimab. We will continue to look at cutting edge diagnostics like Cancer Associated Macrophage-like Cells, or CAMLs, and Circulating Tumor Cell, or CTCs. This will all happen with our collaboration with CreatV MicroTech. We believe CAMLs and CTCs have the potential to provide a minimally invasive alternative to tissue biopsies, to determine cancer therapy and monitor treatment response and recurrence.”